



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

universally pertinent cut-off values that distinguish HGG from LGG. This is attainable through large-scale multicentre prospective series and dictates the standardisation of the multimodal MRI and SPECT imaging protocols and data processing, to facilitate the reproducibility of the encouraging results obtained so far from single-centre studies.

Declaration of interests

The authors declare no conflict of interest.

References

1. Daboudi M, Papadaki E, Vakis A, *et al.* Brain SPECT and perfusion MRI: do they provide complementary information about the tumour lesion and its grading? *Clin Radiol* 2019;**74**:652.e1–652.e19.
2. Roberts HC, Roberts TP, Bollen AW, *et al.* Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. *Acad Radiol* 2001;**8**:384–91.
3. Pope WB, Brandal G. Conventional and advanced magnetic resonance imaging in patients with high-grade glioma. *Q J Nucl Med Mol Imaging* 2018;**62**:239–53.
4. Alexiou G, Tsiouris S, Fotopoulos A. Single-photon emission computed tomography [Neuro-SPECT] imaging of brain tumors. In: Dierckx RAJO, Otte A, de Vries EFJ, *et al.*, editors. *PET and SPECT in Neurology*. Heidelberg, Germany: Springer-Verlag; 2014. p. 881–93.
5. Alexiou GA, Zikou A, Tsiouris S, *et al.* Correlation of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain SPECT with tumour grade and Ki-67 immunohistochemistry in glioma. *Clin Neurol Neurosurg* 2014;**116**:41–5.
6. Fotopoulos AD, Kyritsis AP, Tsiouris S, *et al.* Characterization of intracranial space-occupying lesions by ^{99m}Tc-Tetrofosmin SPECT. *J Neuro-oncol* 2011;**101**:83–9.
7. Barai S, Bandopadhyaya GP, Julka PK, *et al.* Imaging using Tc99m-tetrofosmin for the detection of the recurrence of brain tumour: a comparative study with Tc99m-glucoheptonate. *J Postgrad Med* 2004;**50**:89–93.
8. Tsiouris S, Bougias C, Fotopoulos A. Principles and current trends in the correlative evaluation of glioma with advanced MRI techniques and PET. *Hell J Nucl Med* 2019;**22**:206–19.
9. Tsiouris S, Alexiou G, Papadopoulos A, *et al.* Metabolic imaging of brain tumor by ^{99m}Tc-Tetrofosmin scintitography. In: Abujamra AL, editor. *Diagnostic Techniques and Surgical Management of Brain Tumors*. Rijeka, Croatia: InTech; 2011. p. 303–24.
10. Alexiou GA, Zikou A, Tsiouris S, *et al.* Comparison of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain SPECT for the detection of recurrent high-grade glioma. *Magn Reson Imaging* 2014;**32**:854–9.

S. Tsiouris*, G.A. Alexiou, M.I. Argyropoulou, A.K. Zikou, L.G. Astrakas, A.D. Fotopoulos
 University Hospital of Ioannina, Ioannina, Greece
 * Guarantor and correspondent: S. Tsiouris.
 E-mail address: spytsi@gmail.com (S. Tsiouris)

<https://doi.org/10.1016/j.crad.2019.12.026>

© 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

* Guarantor and correspondent: M.P. Wilson.

COVID-19-related cardiac involvement and potential implications for cardiothoracic imaging



Sir

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). SARS-CoV-2 is a single-stranded RNA enveloped virus, which uses the ACE2 receptor for cellular adherence.¹ Most imaging features reported to date associated with COVID-19 have focused on lung imaging findings as respiratory symptomatology is most common^{2,3}; however, ACE2-expressing cells have been shown to be present in a number of other organs including the myocardium, where nearly 10% of cells demonstrate ACE2 expression.⁴ The heart has therefore been identified as a high risk site for SARS-CoV-2 infection, particularly in patients with prior cardiac injury, diabetes mellitus, and/or hypertension treated with ACE inhibitors or angiotensin receptor blockers (ARB) where there may be unregulated ACE2 expression.^{4,5} Severe myocarditis has already been reported in patients with COVID-19^{6,7} and inflammatory infiltrates in the myocardium have been confirmed on autopsy studies.⁸

The high risk for myocardial involvement in patients with COVID-19 has implications for chest imaging. Firstly, as the number of cases continue to rise, COVID-19 may be an increasingly frequent consideration as a potential cause for viral myocarditis on imaging. Secondly, radiologists should be aware that the number of imaging requests for cardiac imaging in patients with suspected or confirmed COVID-19 are likely to increase in order to explore for potential causes of cardiac injury such as coronary artery disease or myocarditis. Approximately 40% of hospitalised COVID-19 infected patients have coronary artery disease and nearly a quarter of critically ill patients can have cardiac injury.⁹ Differentiating between acute coronary syndromes related to systemic disease and primary cardiac injury will be clinically important for management as treatment remains supportive at present time.⁷ To this end, a specific review for coronary calcification or occult features of ischaemic heart disease on chest computed tomography (CT) should be undertaken. Cardiac magnetic resonance imaging (MRI) could also be considered in patients with suspected or confirmed COVID-19 and with clinical, biochemical, and/or electrocardiography (ECG) changes suggestive of myocardial injury but without an acute coronary syndrome.

Conflict of interest

The authors declare no conflict of interest

References

1. Paules CI, Marston HD, Fauci AS. Coronavirus infections — more than just the common cold. *JAMA* 2020 Jan;**23**, <https://doi.org/10.1001/jama.2020.0757>.

2. Kong W, Agarwal PP. Chest imaging appearances of COVID-19 infection. *Radiol Cardiothorac Imag* 2020 Feb;**13**, <https://doi.org/10.1148/ryct.2020200028>.
3. Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. *Radiology* 2020 Feb;**20**:200463. <https://doi.org/10.1148/radiol.2020200463>.
4. Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med* 2020 Mar;**12**, <https://doi.org/10.1007/s11684-020-0754-0>.
5. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med* 2020 Apr;**8**(4):e21. [https://doi.org/10.1016/S2213-2600\(20\)30116-8](https://doi.org/10.1016/S2213-2600(20)30116-8).
6. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA Cardiol* 2020 Mar;**27**, <https://doi.org/10.1001/jamacardio.2020.1096>.
7. Hu H, Ma F, Wei X, et al. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. *Eur Heart J* 2020 Mar;**16**, <https://doi.org/10.1093/eurheartj/ehaa190>, pii: ehaa190.
8. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020 Apr;**8**(4):420–2. [https://doi.org/10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X).
9. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. *JAMA Cardiol* 2020 Mar;**27**, <https://doi.org/10.1001/jamacardio.2020.1286>.

M.P. Wilson*, R.A. Coulden, G. Low
University of Alberta, Edmonton, Alberta, Canada
* Guarantor and correspondent: M.P. Wilson.
E-mail address: mitch.wilson@ualberta.ca (M.P. Wilson)

<https://doi.org/10.1016/j.crad.2020.04.004>

© 2020 The Royal College of Radiologists. Published by Elsevier Ltd.
All rights reserved.

* Guarantor and correspondent: M.P. Wilson.